Inflammatory Condition Articles & Analysis
32 news found
To address this need, Protheragen-ING continues to prove itself as a top supplier of nonsteroidal anti-inflammatory APIs (NSAIDs), a class of anti-inflammatory APIs. These widely used compounds are helpful to manage various inflammatory conditions such as arthritis, musculoskeletal injuries, toothaches, menstrual pain and ...
Pulmonary arterial hypertension (PAH) is a progressive, life-threatening condition characterized by increased pulmonary arterial pressure, vascular remodeling, and persistent inflammation. ...
Recent advances in the fight against severe acute inflammatory lung diseases, including COVID-19, have revealed a promising new approach to treating pulmonary hyperinflammation and long-term lung damage such as fibrosis. A groundbreaking study has developed a first-in-class, carbohydrate-coupled inhibitor of microRNA-21 (RCS-21), which shows significant potential as a therapeutic agent. This ...
Gesynta Pharma AB today announces the decision to advance the development of its clinical-stage drug candidate GS-248 in endometriosis - a chronic inflammatory condition affecting approximately 10 percent of all women of reproductive age. ...
“Our current focus is cancer, but there’s other diseases where our EXO-NET technology applies, including neurodegenerative diseases, inflammatory diseases and cardio-metabolic conditions,” Dr Hinch said. ...
("AOBiome"), a leading clinical-stage microbiome company focusing on the research and development of a novel class of drugs for inflammatory conditions, central nervous system disorders, and other systemic diseases, today announced that Dr. ...
Ex vivo studies show that treatment with IO-108 produces pro-inflammatory activity and an enhanced antigen-presenting cell (APC) phenotype to multiple stimuli, including T cell activators, and STING and TLR agonists. As a single agent, IO-108 reverts the anti-inflammatory myeloid cell phenotype caused by “tumor conditioning” to ...
They bring a combined experience of over 100 years in research and clinical care of people dealing with chronic pain and inflammatory conditions. Panag's development pipeline of pain relief products include topical, oral, and ocular delivery solutions for challenging molecules. ...
“We believe that CAR-Tregs are the next frontier of cell therapy and represent a potentially transformational approach to solid organ transplantation as well as to many challenging autoimmune and inflammatory conditions. The STEADFAST Phase 1/2 study is an important milestone for genomic medicine that we anticipate will yield insights regarding CAR-Treg ...
Patients at Higher Risk of Wound Infections Some urgent care patients may have underlying conditions that could increase their risk of wound infections either due to the condition itself or the drugs used to treat it. ...
AOBiome Therapeutics, a clinical stage biotechnology company focused on transforming human health by developing topical biologic therapies for systemic inflammatory conditions, announced positive pivotal Phase 2b results from its trial evaluating B244 in both pruritus (itch) and appearance of atopic dermatitis (eczema). ...
In addition to previously demonstrating the preclinical use of siRNAs for treating inflammatory conditions, this latest publication demonstrates the ability to knockdown endogenous genes, including Ctnnb1, the gene encoding for beta-catenin, which plays a role in tumorigenesis in colorectal cancers, for example. ...
GALWAY, Ireland–Neurent Medical, a company pioneering innovative treatments for chronic inflammatory sino-nasal diseases, today announced Food and Drug Administration (FDA) clearance of its proprietary NEUROMARK™ Rhinitis Neurolysis Therapy™ (RNT). ...
Additionally, recently published immunology data demonstrates that B244 can reduce the inflammatory and pruritic cytokines IL-4, IL-5, IL-13, and IL-31. About AOBiome Therapeutics, Inc. AOBiome Therapeutics, Inc. is a Cambridge, MA-based life sciences company focused on transforming human health by developing topical biologic therapies for local, nasal and systemic ...
There are currently no drugs specifically approved to treat IL-18 driven monogenic HLH and severe inflammatory conditions; disability and death are common outcomes. Dr. Michael Soldan, CEO of AB2 Bio commented: “We are pleased to expand this Phase 3 trial of Tadekinig alfa to adults and thus offering participation in this trial to a wider patient ...
(“AOBiome”), a leading clinical-stage microbiome company focusing on inflammatory conditions, has announced the completion of a cosmetic study investigating the safety and effects of its novel AOB formulation on subjects with mild to moderate eczema. ...
This is the platform that is used to screen for disease indications such as bacterial and viral respiratory tract infections, Group B Streptococcus infection, lung cancer and other chronic inflammatory respiratory conditions. We are pleased to be able to extend use of this technology from its roots in industrial and environmental applications to making a ...
Atopic Dermatitis is characterised as a chronic relapsing inflammatory skin condition which manifests as itchy, inflamed skin. The addressable global patient population is estimated at 230 million. ...
Study results are expected towards the end of 2021 and will provide the basis for future clinical trials both in systemic sclerosis and potentially other chronic inflammatory diseases. Systemic sclerosis is a progressive, autoimmune disease that leads to serious damage to the microvasculature. ...
The FDA Breakthrough Device Program is intended to help patients receive more timely access to certain technologies that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions. Osteomyelitis is a progressive, inflammatory infection of the bone, usually caused by bacteria and is ...